4月14日 - ** 生物技术公司Grace Therapeutics GRCE.O股价盘前上涨3.5%至3.95美元
** 该公司称其实验性注射药物GTx-104在动脉瘤性蛛网膜下腔出血（一种由脑表面出血引起的罕见卒中）的后期试验中达到了主要目标。
** 试验显示，与目前的标准口服尼莫地平相比，危险低血压的发生率降低了 19%。
** 称更多接受GTx-104治疗的患者能够接受更高的剂量，90天后的恢复效果更好
** 称各组副作用相似，未发现新的安全问题
** 表示计划寻求监管部门的批准，并将在本月晚些时候举行的神经病学会议上公布全部数据
** 截至上次收盘，该公司股价年累计上涨约 8%。
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.